MKI67 and sarcoma: While the mitotic rate remains a part of the grading system for sarcomas, the proliferative index (PI), as measured by Ki-67 monoclonal antibody expression (by immunohistochemistry), is also being used as a biomarker to evaluate tumour cell progression and predicting therapeutic responses [3,4,5].